ArticleNPJ breast cancer2024

Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Sara A Hurvitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.